| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.2 | 2e-05 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.14 | 3e-05 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.21 | 0.0001 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0003 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0005 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.16 | 0.0007 |
| mRNA | Ispinesib Mesylate | GDSC1000 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.001 |